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We could confirm pancreatic atrophy as a novel adverse 
event of sorafenib therapy in HCC patients, correlating with 
sorafenib dose and exposure time.  © 2015 S. Karger AG, Basel 
 Introduction 
 The multikinase inhibitor sorafenib is the first chemo-
therapeutic drug that showed a survival benefit in ad-
vanced hepatocellular carcinoma (HCC)  [1, 2] . However, 
sorafenib therapy is limited by side effects and lack of 
long-term efficacy. The most frequent side effects include 
diarrhea and hand-foot skin reaction (HFSR) and often 
lead to discontinuation or dose reduction of sorafenib. 
However, development of early skin toxicity  [3] or diar-
rhea  [4, 5] under sorafenib treatment was associated with 
a better outcome in HCC patients. Recently, pancreatic 
atrophy has been reported as a novel, long-term side effect 
of sorafenib treatment in 2 HCC patients receiving 
sorafenib for 2.5 and 3 years, respectively  [6] . Having de-
veloped grade 2 diarrhea after 3 months of sorafenib treat-
ment, the first patient showed a 20% volume reduction of 
the pancreas after 7 months of sorafenib. The second pa-
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 Abstract 
 Objective: To date, sorafenib is the only approved systemic 
therapy for advanced hepatocellular carcinoma (HCC). Pan-
creatic atrophy has recently been reported in 2 patients as a 
novel side effect after long-term sorafenib treatment.  Meth-
ods: We retrospectively analyzed clinical and radiological 
data of patients with advanced HCC with long-term treat-
ment of sorafenib (median 279 days, range 153–826 days). 
Pancreata were semi-manually segmented section by sec-
tion to calculate the pancreas volumes before and under 
sorafenib treatment.  Results: Sorafenib reduced pancreatic 
volume in 18/19 (95%) HCC patients with a mean pancreatic 
volume loss of 25% (p = 0.002). Pancreatic volume loss de-
pended on the dose (r = 0.36) and exposure time of sorafenib 
(r = 0.35) and was detectable as early as after 3 months of 
sorafenib treatment and already after a cumulative sorafenib 
dose of <100 g. Median overall survival was 13.2 months 
(range 7.8–31.3 months) but did not correlate with sorafenib-
induced pancreatic volume reduction (hazard ratio 1.002, 
95% confidence interval 0.981–1.060, p = 0.24).  Conclusion: 
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tient developed grade 1 diarrhea 2 months after initiation 
of sorafenib and showed a 35% volume reduction of the 
pancreas after 37 months of sorafenib treatment.
 The aim of our current study was to reappraise the 
finding of sorafenib-associated pancreatic atrophy in a 
larger cohort of HCC patients and to determine the cor-
relation between pancreatic atrophy and both the dura-
tion and the cumulative dose of sorafenib exposure. Fur-
thermore, we aimed to analyze the correlation between 
pancreatic atrophy and the patients’ survival.
 Material and Methods 
 Patients 
 We retrospectively analyzed clinical and radiological data from 
advanced HCC patients with long-term sorafenib treatment who 
were monitored by computed tomography (CT) at a 3-month in-
terval at our institution between January 2008 and December 2012. 
Diagnosis of HCC was established according to the recommenda-
tions of the American Association for the Study of Liver Diseases 
 [7] . Inclusion criteria were age >18 years, compensated liver cir-
rhosis (Child-Pugh score A–B), sorafenib treatment >5 months, 
and ECOG performance status 0–3. Exclusion criteria comprised 
patients with pancreatic lesions, previous pancreatic operations, 
and pretreatment with sorafenib or other chemotherapies. This 
study was approved by the local Ethics Board (S-300/2011). Of 88 
HCC patients treated with sorafenib, we had to exclude 47 who 
were on sorafenib for <5 months, 6 who were lost to follow-up, 1 
with sorafenib pretreatment, and 36 who were not monitored by 
CT at a 3-month interval (mainly due to MRI follow-up). We iden-
tified 19 eligible patients with available consecutive high-quality 
CT scans before and under sorafenib treatment. Clinical data were 
retrospectively collected regarding age, gender, underlying liver 
disease, treatment duration and cumulative dose of sorafenib, on-
set and grade of sorafenib side effects according to the National 
Cancer Institute Common Toxicity Criteria for Adverse Events 
version 4.0 (diarrhea, HFSR), second-line treatment (n = 1), and 
overall survival. The patient with second-line therapy received the 
oral histone deacetylase-inhibitor resminostat after progression 
under sorafenib treatment. Detailed data on the study population 
is given in  table 1 .
 Sorafenib Treatment 
 Sorafenib treatment was performed as previously described  [4] . 
Briefly, the starting dose of sorafenib was 400 mg b.i.d. In patients 
with impaired liver function (bilirubin >3 mg/dl), the initial 
sorafenib dose was 200 mg b.i.d., which, in case of good tolerability, 
was escalated after 2–4 weeks up to 400 mg b.i.d. Dose reduction was 
performed in patients with moderate toxic side effects (grade 2), 
with a dose reescalation upon resolution of side effects. In case of 
grade 3 toxicity, sorafenib therapy was interrupted until improve-
ment of side effects to grade 0–1, followed by a permanent dose re-
duction. In parallel, mild and moderate diarrhea was treated with 
loperamide. All patients received prophylaxis of skin toxicity with 
urea-containing ointment. Cumulative sorafenib exposure time and 
dose at the time point of each CT scan was quantified for all patients.
 CT Scanning and Image Processing 
 Tumor response was evaluated by contrast-enhanced ab-
dominal CT scans with portal venous phase on a 128-slice dual-
energy CT scanner (SOMATOM Definition Flash; Siemens 
Healthcare Sector, Forchheim, Germany) with the following 
scan parameters: contrast-enhanced dual-energy CT was per-
formed on the 64-slice dual-energy CT scanner (SOMATOM 
Definition Flash; Siemens Healthcare Sector). All patients were 
scanned in craniocaudal direction from the dome of the liver to 
the iliac crest during inspiratory breath hold. Iodinated contrast 
medium (Iomeprol-400, Iomeron, Bracco Imaging SpA, Milan, 
Italy) was intravenously administered via an automated dual-
syringe power injector (Accutron CT-D, Medtron, Saarbrücken, 
Germany) according to a body weight (mean 68 ± 15 kg)-adapt-
ed injection protocol. Mean contrast amount was 97 ± 9 ml. The 
flow rate was 3.9 ± 0.3 ml/s. The timing for the arterial phase 
scan was determined using the care bolus technique (Siemens 
Healthcare), i.e., arterial phase scan was automatically started
7 s after the attenuation coefficient of abdominal aortic blood 
 Table 1.  Patient characteristics
Total number 19
Male/female 14 (74)/5 (26)
Median age at sorafenib start, years 71.0 (46 – 85)
Liver cirrhosis/no cirrhosis 17 (89)/2 (11)
Median body mass index 26.1 (19.8 – 35.6)
Etiology of liver cirrhosis
Alcohol 5 (29)
Viral hepatitis 3 (18)
Nonalcoholic steatohepatitis 2 (12)
Hemochromatosis 2 (12)
Cryptogenic 5 (29)
Median exposure time to sorafenib, days 279 (153 – 826)
Median cumulative sorafenib dose, g 144 (12 – 516)
Median daily sorafenib dose, mg 565 (400 – 800)
Diarrhea, grade
0 3 (16)
1 11 (58)
2 3 (16)
3 2 (11)
HFSR, grade
0 11 (58)
1 2 (11)
2 2 (11)
3 4 (21)
Weight loss, grade
0 7 (37)
1 8 (42)
2 4 (41)
Median overall survival, days 396 (233 – 940)
Values in parentheses are percentages (percentage of cirrhotic 
patients for etiology of liver cirrhosis) or ranges. Adverse events 
are graded according to the National Cancer Institute Common 
Toxicity Criteria for Adverse Events version 4.0.
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reached 120 Hounsfield units. The portal venous phase images 
were acquired another 30 s after the arterial phase examination. 
Contrast application was the same for the individual patient at 
every imaging time point. The scan was acquired with a detector 
collimation of 32 × 0.6 mm, slice 3.0 mm, rotation time 0.5 s, and 
pitch 0.6.
 Abdominal CT scans were performed before and approximate-
ly every 12 weeks under sorafenib treatment. For volumetric anal-
ysis, the complete pancreas was semi-manually segmented section 
by section in both coronal and sagittal reconstruction by 2 radi-
ologists (M.-K.G. and M.S.), who were blinded for the treatment 
phase of the respective CT scan. Arterial phase images were in-
cluded in our analysis in order to differentiate organ borders using 
an in-house-developed software (MITK Version 2011; DKFZ, 
Heidelberg, Germany)  [8, 9] . The organ was segmented by exploit-
ing the local gray-value statistics of the pancreas tissue ( fig. 1 ). To 
minimize potential measurement errors, organs were segmented 
three times, and the mean value of these volume measurements 
was used for further analysis.
 Statistical Analysis 
 The variables were analyzed descriptively by tabulation of the 
measures of the empirical distributions. According to the scale lev-
el of the variables, means, standard deviations, medians as well as 
minimum and maximum or absolute and relative frequencies, re-
spectively, were reported. Survival of the patients was reported us-
ing the Kaplan-Meier method. A possible association between 
continuous variables was investigated using Pearson’s correlation 
coefficients. Descriptive p values of the corresponding statistical 
tests were calculated. Wherever appropriate, statistical graphics 
were used to illustrate the findings.
 Results 
 Patient Characteristics 
 For our analysis, we included 19 patients who were 
treated with sorafenib for advanced hepatocellular cancer 
over a median of 279 days (range 153–826 days). The 
baseline characteristics of our population are listed in  ta-
ble 1 . In all patients, treatment with sorafenib was finally 
stopped due to significant and/or symptomatic tumor 
progression. Only 1 patient received a second-line treat-
ment after HCC progression after 8.2 months (245 days) 
of sorafenib therapy. This patient demonstrated an over-
all survival of 28.9 months (866 days).
 Sorafenib-Induced Side Effects 
 Diarrhea and HFSR were common side effects of 
sorafenib treatment. Their frequencies are listed in  ta-
ble  1 . Diarrhea occurred on average after 89 days of 
sorafenib treatment (range 3–385 days), HFSR after 53 
days of sorafenib treatment (range 14–249 days). Accord-
ingly, ‘early’ and ‘late’ HFSR were defined when occur-
ring <50 days versus >50 days after the onset of sorafenib, 
respectively. However, due to consequent prophylaxis of 
HFSR with urea-containing ointment, this side effect was 
comparably mild and rare.
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 Fig. 1. Measurement of the pancreatic vol-
ume. An example of the semi-manual seg-
mentation of the organ is shown. The 
boundaries of the pancreas are highlighted 
in red (in the online version only). 
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 Fig. 2. Sorafenib-induced pancreatic atrophy.  a Mean pancreas vol-
ume reduction from 58.6 ml (median volume 55.0 ml) before the on-
set of sorafenib to 44.1 ml (median volume 43.0 ml) under sorafenib 
treatment (p = 0.0002).  b Example of a three-dimensional volume 
reconstruction of the pancreas before and after a 240-day treatment 
interval with sorafenib with a cumulative dose of 51.2 g.  c Absolute 
pancreas volumes of all individual patients before sorafenib treat-
ment are compared to the last CT scan under sorafenib treatment.
 d ,  e Relative pancreas volumes (compared to a starting volume of 
100%) under sorafenib treatment are shown as a function of the cu-
mulative dose ( d ) and the exposure time to sorafenib ( e ). The corre-
lation coefficient r is given for both graphs. 
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 Volumetric Analysis of the Pancreas under Sorafenib 
Treatment 
 The last CT scan before the onset of sorafenib, defin-
ing the reference CT with the relative pancreas volume 
set to 100%, was performed at a mean of 42 days (range 
0–207 days) before the start of treatment. However, ra-
diological imaging was performed in all patients at least 
30 days before sorafenib treatment. Some imaging was 
performed by MRI, ruling out significant pancreatic 
volume changes before sorafenib treatment. For a better 
comparability of volumetric data before and under 
treatment, only CT scans were considered for this anal-
ysis. On average, 2.7 CT scans (range 1–5) were per-
formed per patient under sorafenib treatment. The final 
CT scan under sorafenib was performed after a median 
sorafenib treatment time of 227 days (range 123–552 
days). These data sets were used to calculate the pan-
creas volume before and under sorafenib treatment, 
measured after the respective maximal sorafenib expo-
sure time.
 Sorafenib treatment of HCC patients significantly re-
duced the mean pancreas volume from 58.6 ml before the 
onset of sorafenib to 44.1 ml under sorafenib treatment 
(p = 0.0002), resulting in a mean volume reduction by 
14.5 ml (25%;  fig. 2 a). An example of a three-dimension-
al volume reconstruction of the pancreas before and un-
der sorafenib treatment is shown in  figure 2 b, demon-
strating a significant sorafenib-induced volume loss of 
the pancreatic head.
 Figure 2 c compares the individual changes of pancreas 
volumes before and under sorafenib treatment for all 19 
patients. Sorafenib reduced pancreatic volume in all but 
1 patient. The maximal pancreas volume reduction was 
55.8 ml (51%) after 455 days of sorafenib treatment, with 
a cumulative sorafenib dose of 325 g at the time point of 
the last CT scan under sorafenib. Only 1 patient showed 
an increase of the pancreas volume from 19.4 to 24.3 ml 
(increase by 25%) after 284 days of sorafenib treatment, 
with a cumulative dose of 131 g at the time point of the 
last CT scan under sorafenib.
 In  figure 2 d and e, the relative pancreas volumes under 
sorafenib treatment compared to the reference CT scan 
before the onset of treatment (set as 100%) are plotted as 
a function of the administered cumulative dose of 
sorafenib ( fig.  2 d) or the exposure time of sorafenib 
( fig.  2 e) for all patients and including all available CT 
scans under therapy. Pancreatic atrophy demonstrates a 
dependence on the dose (r = 0.36) and exposure time of 
sorafenib (r = 0.35), with a wide variety of initial pancre-
as volumes within the whole population ( fig. 2 c).
 Correlation of Pancreatic Atrophy with Clinical 
Parameters 
 Since sorafenib-induced diarrhea and HFSR have been 
discussed as predictors of positive outcome under 
sorafenib therapy  [4, 5] , we sought to investigate whether 
these side effects are interlinked with the newly described 
sorafenib-induced pancreatic atrophy  [6] and whether 
pancreatic atrophy is correlated with better outcome of 
HCC patients as well. In our cohort, there was no correla-
tion between the degree of pancreatic shrinkage and the 
onset (r = –0.05) or grade (r = 0.11) of sorafenib-induced 
diarrhea. However, sorafenib-induced volume reduction 
0
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 Fig. 3. Sorafenib-induced pancreatic atrophy and survival.  a Kap-
lan-Meier curve for the overall survival of all sorafenib-treated 
HCC patients.  b Pancreatic volume reduction does not correlate 
with the overall survival (hazard ratio 1.002, 95% confidence inter-
val 0.981–1.060, p = 0.24). 
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of the pancreas positively correlated with a later onset 
(>50 days after sorafenib onset, r = 0.52) but not with the 
grade (r = –0.07) of HFSR. Analyzing the overall survival 
of our cohort, we found a median overall survival of 13.2 
months (396 days), with a median sorafenib exposure 
time of 9.3 months (279 days). The Kaplan-Meier curve 
for the overall survival of the whole study population is 
shown in  figure 3 a. Sorafenib-induced pancreatic volume 
loss did not correlate with the patients’ overall survival 
(hazard ratio 1.002, 95% confidence interval 0.981–1.060, 
p = 0.24;  fig. 3 b).
 Discussion 
 To date, sorafenib is the only approved systemic ther-
apy for patients with advanced HCC (Barcelona Clinic 
Liver Cancer stage C)  [10] . Recently, pancreatic atrophy 
has been reported in 2 patients as another novel side effect 
of long-term sorafenib treatment  [6] . In that report, a 20 
and 35% decrease in the volume of the pancreas was ob-
served after 7 and 37 months of sorafenib treatment, re-
spectively. A cumulative sorafenib dose of >1,000 g and a 
treatment duration of >24 months was reported in these 
2 long-term treated HCC patients.
 In our current study we sought to confirm this ob-
servation in a larger cohort. We found that 18/19 (95%) 
of our HCC patients developed pancreatic volume re-
duction as a continuous process under sorafenib treat-
ment, being detectable already in the first control CT 
scan after 3–4 months of sorafenib exposure in the ma-
jority of patients ( fig.  2 e). Considerable pancreatic 
shrinkage was observed already after a cumulative 
sorafenib dose of <100 g ( fig. 2 d). Although there is a 
considerable variation in the pancreas volumes before 
the onset of treatment ( fig. 2 c), the volume reduction by 
sorafenib was statistically significant in the whole co-
hort of patients ( fig. 2 a). It has been discussed that pan-
creatic exocrine insufficiency could contribute to 
sorafenib-induced diarrhea  [11] . Accordingly, Hescot 
et al.  [6] found steatorrhea in 1 of the 2 HCC patients 
who could be successfully treated with pancreatic en-
zyme replacement. Due to the lack of data on stool elas-
tase or steatorrhea in our retrospective analysis, we can-
not comment on this aspect of sorafenib-induced diar-
rhea. However, since the early onset of diarrhea (at a 
median of 89 days) was paralleled by an early pancre-
atic volume loss after at least 90–120 days of sorafenib 
treatment, shrinkage-induced exocrine pancreatic in-
sufficiency might indeed contribute to sorafenib-in-
duced diarrhea. In our cohort, we could not detect a 
significant correlation between pancreatic volume loss 
and sorafenib-induced diarrhea, which might, howev-
er, be biased by the preemptive therapy with loper-
amide. In contrast, the extent of pancreatic volume loss 
correlated with a late onset of HFSR. This observation 
might be explained by the fact that patients with a late 
onset of HFSR (due to consequent prophylaxis by oint-
ments) did not need an early sorafenib dose reduction, 
leading to a higher cumulative sorafenib dose, which in 
turn correlated with pancreatic volume reduction 
( fig. 2 d). Accordingly, we calculated a median cumula-
tive sorafenib dose of 88 versus 146 g in patients with 
early (<50 days) and late (>50 days) HFSR, respectively. 
However, since only 8 patients of our cohort developed 
HFSR (4 with early HFSR), a scrutinized or even multi-
variate analysis of the interdependence of HFSR and 
pancreatic atrophy is impossible.
 The antiangiogenic properties of sorafenib might ac-
count for a reduced microvasculature in both tumor and 
normal tissue, leading to the atrophy of the pancreas  [6] , 
muscle  [12] , and thyroid gland  [13] , and possibly also to 
frequent side effects like diarrhea and HFRS. Thus, a 
higher frequency and grade of antiangiogenic side effects 
might be associated with a stronger antitumor effect by 
and a higher survival benefit from sorafenib treatment. 
Accordingly, the occurrence of diarrhea  [4, 5] and/or ear-
ly HFSR  [3, 14–16] and the presence of adverse events in 
general  [17] have been reported to be associated with a 
favorable outcome in HCC and renal cell cancer patients 
under sorafenib. However, in our cohort with an overall 
survival ranging from 233 to 940 days ( table 1 ), pancre-
atic volume reduction was not associated with a longer 
survival time.
 The previously discussed issues already illustrate the 
limitations of our hypothesis-generating study: the retro-
spective nature of our analysis limits the generalization of 
its statements. In 2 patients, the last CT scan prior to 
sorafenib treatment was performed 92 and 207 days be-
fore the onset of sorafenib, respectively. In these patients, 
significant changes of pancreatic volumes before sorafenib 
treatment were ruled out by additional MRI scans that 
had been performed within 90 days before sorafenib 
treatment. For a better comparability of volumetric mea-
surements, MRI data were not included in our analysis. 
All other patients had baseline CT scans within 90 days 
before sorafenib treatment. Furthermore, data regarding 
steatorrhea or lipase levels are lacking. A large prospec-
tive observational study is needed to clarify these intrigu-
ing issues.
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